Information Provided By:
Fly News Breaks for June 14, 2018
MYL
Jun 14, 2018 | 07:38 EDT
Morgan Stanley analyst David Risinger called Mylan's announcement that generic Advair will not be approved by its June 27 action date a "small negative, but not a major surprise." He sees potential for approval this fall, while noting that the company previously warned with its Q1 earnings release that there was risk that it could need to lower its 2018 guidance range. He keeps an Overweight rating on Mylan shares, citing the stock's low valuation and the company's pipeline opportunities.
News For MYL From the Last 2 Days
There are no results for your query MYL